Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving patients' lives through peptide drug discovery and development. They focus on unmet needs across rare and prevalent diseases, leveraging a groundbreaking peptide technology platform to engineer powerful drug candidates. Their mission is to bring forward novel peptide therapeutics with the potential to radically improve treatment options for various diseases, supported by visionary leadership and a commitment to diversity, equity, and sustainability.
Industries
Nr. of Employees
medium (51-250)
Protagonist Therapeutics, Inc.
7707 Gateway Boulevard, Suite 140, Newark, CA 94560-1160 USA
Patents
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US-12018057-B2
View DetailsOral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US-11884748-B2
View DetailsPeptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US-11845808-B2
View Details
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US-12018057-B2
View DetailsOral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US-11884748-B2
View DetailsPeptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US-11845808-B2
View DetailsProducts
Hepcidin-mimetic peptide for polycythemia vera (late-stage)
A peptide-based hepcidin mimetic developed to modulate iron regulation and address erythrocytosis in polycythemia vera; advanced in late-stage clinical development.
Oral IL-23 receptor peptide antagonist (Phase 3)
An orally delivered peptide antagonist of the IL-23 receptor evaluated in late-stage clinical development for inflammatory indications.
Oral α4β7 integrin peptide antagonist for ulcerative colitis (Phase 2)
A gut-restricted oral peptide antagonist of the α4β7 integrin developed for the treatment of moderate to severe ulcerative colitis; evaluated in randomized Phase 2 studies.
Hepcidin-mimetic peptide for polycythemia vera (late-stage)
A peptide-based hepcidin mimetic developed to modulate iron regulation and address erythrocytosis in polycythemia vera; advanced in late-stage clinical development.
Oral IL-23 receptor peptide antagonist (Phase 3)
An orally delivered peptide antagonist of the IL-23 receptor evaluated in late-stage clinical development for inflammatory indications.
Oral α4β7 integrin peptide antagonist for ulcerative colitis (Phase 2)
A gut-restricted oral peptide antagonist of the α4β7 integrin developed for the treatment of moderate to severe ulcerative colitis; evaluated in randomized Phase 2 studies.
Services
Design and operate clinical studies and provide access to investigational therapies via trials and long-term extension programs.
Strategic partnering and co-development services with larger pharmaceutical organizations to advance clinical development and commercialization.
Preparation and dissemination of preclinical and clinical data through peer-reviewed publications and conference presentations.
Design and operate clinical studies and provide access to investigational therapies via trials and long-term extension programs.
Strategic partnering and co-development services with larger pharmaceutical organizations to advance clinical development and commercialization.
Preparation and dissemination of preclinical and clinical data through peer-reviewed publications and conference presentations.
Expertise Areas
- Peptide drug discovery and optimization
- Oral peptide formulation and gut-restricted delivery
- Late-stage clinical development (Phase 2/3)
- Preclinical and clinical pharmacology (PK/PD)
Key Technologies
- Peptide therapeutics platform
- Combinatorial chemistry
- Molecular design
- Phage display